Aripiprazole in autism spectrum disorders and fragile X syndrome

Neurotherapeutics

Volumn 7, Issue 3, 2010, Pages 258-263

  Erickson, Craig A ^a,b   Stigler, Kimberly A ^a,b   Posey, David J ^a,b   McDougle, Christopher J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Aripiprazole; Autistic disorder; Fragile X syndrome; Irritability

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; KETOCONAZOLE; PAROXETINE; QUINIDINE; RISPERIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AGITATION; ARTICLE; AUTISM; BIPOLAR MANIA; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL FEATURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FRAGILE X SYNDROME; HEART RATE; HUMAN; HYPERSALIVATION; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MYALGIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RIGIDITY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE;

ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FRAGILE X SYNDROME; HUMANS; PIPERAZINES; QUINOLONES;

EID: 77954950453     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.04.001     Document Type: Article

References (39)

1. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, American Psychiatric Association, Washington, D.C. 4th Ed, text revision.
2. Kogan M.D., Blumberg S.J., Schieve L.A., et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009, 124:1395-1403.
3. Erickson C.A., Posey D.J., Stigler K.A., McDougle C.J. Pharmacologic treatment of autism and related disorders. Pediatr Ann 2007, 36:575-585.
4. Berry-Kravis E., Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev 2004, 10:42-48.
5. Hatton D.D., Sideris J., Skinner M., et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006, 140A:1804-1813.
6. Bailey D.B., Hatton D.D., Skinner M., Mesibov G. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. J Autism Dev Disord 2001, 31:165-174.
7. Bailey D.B., Raspa M., Olmsted M., Holiday D.B. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008, 146A(16):2060-2069.
8. Erickson C.A., Stigler K.A., Posey D., McDougle C. Managing maladaptive behaviors in fragile X patients. Curr Psychiatry 2006, 5:80-92.
9. Hessl D., Rivera S., Koldewyn K., et al. Amygdala dysfunction in men with the fragile X premutation. Brain 2007, 130(Pt 2):404-416.
10. Hessl D., Tassone F., Loesch D.Z., et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 2005, 139B(1):115-121.
11. Johnston C., Eliez S., Dyer-Friedman J., et al. Neurobehavioral phenotype in carriers of the fragile X premutation. Am J Med Genet 2001, 103:314-319.
12. Shapiro D.A., Renock S., Arrington E., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28:1400-1411.
13. Burris K.D., Molski T.F., Xu C., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002, 302:381-389.
14. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002, 441:137-140.
15. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics?. A review of the evidence. Neuropsychopharmacology 1998, 18:63-101.
16. Kikuchi T., Tottori K., Uwahodo Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995, 274:329-336.
17. Inoue A., Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 2001, 86:376-380.
18. Casey D.E., Carson W.H., Saha A.R., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166:391-399.
19. Aripiprazole prescribing information 2009, 1-77. Bristol-Myers_Squibb, Otsuka_America_Pharmaceutical_Inc., Otsuka Pharmaceuticals Co., Ltd, Tokyo, Otsuka Pharmaceuticals Co., Ltd.
20. Stigler K.A., Posey D.J., McDougle C.J. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004, 14:455-463. Fall.
21. Guy W. ECDEU assessment manual for psychopharmacology, Publication No. 76-338 1976, U.S. DHEW, NIMH, Washington, DC.
22. Stigler K.A., Diener J.T., Kohn A.E., et al. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009, 19:265-274.
23. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 5:485-491.
24. Valicenti-McDermott M.R., Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006, 16:549-560.
25. Masi G., Cosenza A., Millepiedi S., Muratori F., Pari C., Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009, 23:511-521.
26. Owen R., Sikich L., Marcus R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
27. Marcus R.N., Owen R., Kamen L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
28. Aman M.G., Kasper W., Manos G., et al. Aripiprazole in the treatment of irritability associated with autistic disorder in children and adolescents (6-17 years old): Line-item analysis of the Aberrant Behavior Checklist Irritability Subscale 2009, 56th American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI.
29. Mankoski R., Manos G., Chambers J., et al. Effect of cognitive ability on aripiprazole treatment of irritability associated with autistic disorder 2009, 56th American Academy of Child & Adolescent Psychiatry Meeting, Honolulu, HI.
30. Robb A., Rojas-Fernandez C., Mankoski R., et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder 2009, 56th American Academy of Child and Adolescent Psychiatry Meeting, Honolulu, HI.
31. McCracken J.T., McGough J., Shah B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321.
32. Shea S., Turgay A., Carroll A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
33. Anderson G.M., Scahill L., McCracken J.T., et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007, 61:545-550.
34. Amaria R., LL B., R H. Medication use in fragile X syndrome. Mental Health Asp Dev Dis 2001, 4:89-93.
35. Hagerman R.J., Berry-Kravis E., Kaufmann W.E., et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009, 123:378-390.
36. Erickson C.A., Mullett J., Diener J.T., et al. Open-label aripiprazole in Fragile X Syndrome 2009, National Clinical and Translational Research Annual Meeting, Washington, D.C.
37. McDougle C.J., Erickson C.A., Stigler K.A., Posey D.J. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 66(suppl 10):9-18.
38. United States National Institutes of Health, Clinicaltrials.gov, Accessed February 9, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00198107.
39. United States National Institutes of Health, Clinicaltrials.gov, Accessed February 9, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00870727.